Randall Davis is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
619 19th Street South
Birmingham, AL 35233
Telephone
205-934-6600Registry record last updated 29 Jun 2023.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73%Kinase inhibitor62.4%Calquence72%Imbruvica23%Imatinib Mesylate5%Part D<11 patientsBCL-2 Inhibitor7.1%Venclexta100%Part D<11 patients+ 1 more class in this area
Anti-infectives
10.3%Nucleoside and nucleotide reverse transcriptase inhibitors3.7%Vemlidy100%Part D<11 patientsAzole Antifungal3.4%Fluconazole100%Part D<11 patients+ 1 more class in this area
Dermatology
9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- FCRL Regulation in B Cell Tolerance and Malignancy
University of Alabama at Birmingham
FY2026$496,628R01AI189667 - Roles of FCRL Molecules in Innate Immunity
University of Alabama at Birmingham
FY2019$367,500R01AI110553 - Roles of FCRL Molecules in Innate Immunity
University of Alabama at Birmingham
FY2018$367,500R01AI110553
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”